Results 1 to 10 of about 952,266 (403)

CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions

Frontiers in Oncology, 2020
Relapse after conventional chemotherapy remains a major problem in patients with myeloid malignancies such as acute myeloid leukemia (AML), and the major cause of death after diagnosis of AML is from relapsed disease.
Sherly Mardiana, Saar Gill
exaly   +2 more sources

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) [PDF]

Haematologica, 2008
Acute myeloid leukemia with mutated NPM1 gene and aberrant cytoplasmic expression of nucleophosmin (NPMc+ acute myeloid leukemia) shows distinctive biological and clinical features.
Arcangelo Liso, Filippo Castiglione, Antonio Cappuccio, Fabrizio Stracci, Richard F. Schlenk, Sergio Amadori, Christian Thiede, Susanne Schnittger, Peter J.M. Valk, Konstanze Döhner, Massimo F. Martelli, Markus Schaich, Jürgen Krauter, Arnold Ganser, Maria P. Martelli, Niccolò Bolli, Bob Löwenberg, Torsten Haferlach, Gerhard Ehninger, Franco Mandelli, Hartmut Döhner, Franziska Michor, Brunangelo Falini   +22 more
doaj   +4 more sources

Long-term experience in treatment of acute promyelocytic leukemia in Mexican children in a tertiary care hospital

Frontiers in Oncology, 2023
IntroductionAcute promyelocytic leukemia (APL) is a rare myeloid leukemia subtype affecting adult and pediatric populations. APL constitutes 15-20% of all childhood AML in Latin America, compared to 7% in the non-Latino population.
Marco Antonio Murillo-Maldonado, Paulina González Galván, Israel Parra Ortega, Félix Gaytán Morales, Félix Gaytán Morales, Luis Juárez Villegas, Elisa Dorantes Acosta, Elisa Dorantes Acosta   +7 more
doaj   +1 more source

Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers

Haematologica, 2021
Cancer treatment is constantly evolving from a one-size-fits-all towards bespoke approaches for each patient. In certain solid cancers, including breast and lung, tumor genome profiling has been incorporated into therapeutic decision-making. For chronic
Vaidehi Krishnan, Dennis Dong Hwan Kim, Timothy P. Hughes, Susan Branford, S. Tiong Ong   +4 more
doaj   +1 more source

International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.

Blood, 2022
The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology.
D. Arber, A. Orazi, R. Hasserjian, M. Borowitz, K. Calvo, H. Kvasnicka, Sa A. Wang, A. Bagg, T. Barbui, S. Branford, C. Bueso-Ramos, J. Cortes, P. Dal Cin, C. Dinardo, H. Dombret, E. Duncavage, B. Ebert, E. Estey, F. Facchetti, K. Foucar, N. Gangat, U. Gianelli, L. Godley, N. Goekbuget, J. Gotlib, E. Hellström-Lindberg, G. Hobbs, R. Hoffman, E. Jabbour, J. Kiladjian, R. Larson, M. L. Le Beau, M. Loh, B. Löwenberg, E. Macintyre, L. Malcovati, C. Mullighan, C. Niemeyer, O. Odenike, S. Ogawa, A. Órfão, E. Papaemmanuil, F. Passamonti, K. Porkka, C. Pui, J. Radich, A. Reiter, M. Rozman, M. Rudelius, M. Savona, C. Schiffer, Annette Schmitt-Graeff, A. Shimamura, J. Sierra, W. Stock, R. Stone, M. Tallman, J. Thiele, H. Tien, A. Tzankov, A. Vannucchi, P. Vyas, A. Wei, O. Weinberg, A. Wierzbowska, M. Cazzola, H. Döhner, A. Tefferi   +67 more
semanticscholar   +1 more source

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients

HemaSphere, 2021
Tyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the achievement of deep molecular responses (DMRs), which can eventually lead to therapy discontinuation ...
Natalia Estrada, Blanca Xicoy, Fabian Beier, Olga Garcia, Cristian Morales, Concepción Boqué, Miguel Sagüés, Mónica S. Ventura Ferreira, Rolando Vallansot, Sílvia Marcé, Marta Cabezón, Tim H. Brümmendorf, Lurdes Zamora   +12 more
doaj   +1 more source

Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers

eJHaem, 2021
Acute myeloid leukemia (AML) is associated with a high economic and clinical burden. Recently novel therapies have been added to standard treatment regimens. Here, we evaluated the economic impact of AML up until the introduction of these novel therapies.
Emma Hernlund, Josefine Redig, Björn Paulsson, Åsa Rangert Derolf, Martin Höglund, Simona Vertuani, Gunnar Juliusson   +6 more
doaj   +1 more source

Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management

American journal of hematology/oncology, 2023
Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell cancer characterized by unbridled proliferation of malignant marrow stem cells with associated infection, anemia, and bleeding.
S. Shimony, Maximilian F. Stahl, R. Stone   +2 more
semanticscholar   +1 more source

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2023
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues.
D. Pollyea, J. Altman, R. Assi, D. Bixby, A. Fathi, J. Foran, I. Gojo, Aric Hall, B. Jonas, A. Kishtagari, J. Lancet, L. Maness, J. Mangan, G. Mannis, G. Marcucci, A. Mims, Kelsey Moriarty, Moaath K. Mustafa Ali, Jadee L. Neff, R. Nejati, R. Olin, M. Percival, A. Perl, Amanda C. Przespolewski, D. Rao, F. Ravandi, R. Shallis, P. Shami, E. Stein, R. Stone, K. Sweet, Swapna Thota, G. Uy, P. Vachhani, Carly J Cassara, Deborah A. Freedman-Cass, Katie Stehman   +36 more
semanticscholar   +1 more source

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

New England Journal of Medicine, 2022
BACKGROUND The combination of ivosidenib - an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) - and azacitidine showed encouraging clinical activity in a phase 1b trial involving patients with newly diagnosed IDH1-mutated acute myeloid leukemia ...
P. Montesinos, C. Récher, S. Vives, E. Zarzycka, Jianxiang Wang, Giambattista Bertani, M. Heuser, R. Calado, A. Schuh, S. Yeh, S. Daigle, J. Hui, S. Pandya, D. Gianolio, S. de Botton, H. Döhner   +15 more
semanticscholar   +1 more source